Connect Biopharma Holdings Limited
| NASDAQ: CNTB | - / - / - |
| 0.9501 | -0.0499 | -4.99% | Vol 102.45K | 1Y Perf -23.66% |
| Oct 3rd, 2023 15:59 DELAYED |
| BID | 0.9500 | ASK | 1.02 | ||
| Open | 0.9701 | Previous Close | 1.00 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 5.69 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 498.88 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 39.74 | Earnings Rating | — | |
| Market Cap | 52.29M | Earnings Date | 30th Mar 2023 | |
| Alpha | -0.05 | Standard Deviation | 0.29 | |
| Beta | -0.41 |
Today's Price Range 0.85001.07 | 52W Range 0.53471.58 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 36.99% | ||
| 1 Month | 25.00% | ||
| 3 Months | -11.50% | ||
| 6 Months | -7.41% | ||
| 1 Year | -23.66% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -42.65 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -39.98 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -43.60 | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | -19.09 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.40 | ||||
| 0.23 | ||||
| - | ||||
| - | ||||
| -0.90 | ||||
| -1.64 | ||||
| 0.22 | ||||
| 3.77 | ||||
| -138 560 000.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 9.30 | ||||
| 9.60 | ||||
| 0.00 | ||||
| 0.00 | ||||
| -9 538.90 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.48 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 102.45K |
| Shares Outstanding | 55.04K |
| Shares Float | 18.48M |
| Trades Count | 511 |
| Dollar Volume | 103.30K |
| Avg. Volume | 104.24K |
| Avg. Weekly Volume | 197.07K |
| Avg. Monthly Volume | 75.23K |
| Avg. Quarterly Volume | 40.42K |
Connect Biopharma Holdings Limited (NASDAQ: CNTB) stock closed at 1 per share at the end of the most recent trading day (a 22.1% change compared to the prior day closing price) with a volume of 634.00K shares and market capitalization of 52.29M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the industry, sector and employs 0 people. Connect Biopharma Holdings Limited CEO is .
The one-year performance of Connect Biopharma Holdings Limited stock is -23.66%, while year-to-date (YTD) performance is 15.23%. CNTB stock has a five-year performance of %. Its 52-week range is between 0.5347 and 1.58, which gives CNTB stock a 52-week price range ratio of 39.74%
Connect Biopharma Holdings Limited currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.23, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -39.98%, a ROC of -43.60% and a ROE of -42.65%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Connect Biopharma Holdings Limited, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.48 for the next earnings report. Connect Biopharma Holdings Limited’s next earnings report date is -.
The consensus rating of Wall Street analysts for Connect Biopharma Holdings Limited is Strong Buy (1), with a target price of $5.69, which is +498.88% compared to the current price. The earnings rating for Connect Biopharma Holdings Limited stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Connect Biopharma Holdings Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Connect Biopharma Holdings Limited has a Buy technical analysis rating based on Technical Indicators (ADX : 33.02, ATR14 : 0.11, CCI20 : 266.49, Chaikin Money Flow : 0.50, MACD : -0.01, Money Flow Index : 82.50, ROC : 19.05, RSI : 69.01, STOCH (14,3) : 97.90, STOCH RSI : 1.00, UO : 67.53, Williams %R : -2.10), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Connect Biopharma Holdings Limited in the last 12-months were:
